{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:39:50Z","timestamp":1791866390023,"version":"4.3.4"},"reference-count":92,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1506,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1111\/j.1751-7176.2011.00508.x","type":"journal-article","created":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T12:41:46Z","timestamp":1310992906000},"page":"667-675","source":"Crossref","is-referenced-by-count":99,"title":["Angiotensin-Converting Enzyme Inhibitors"],"prefix":"10.1111","volume":"13","author":[{"given":"Joseph L.","family":"Izzo Jr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,18]]},"reference":[{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1126\/science.191908","article-title":"Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents","volume":"196","author":"Ondetti","year":"1977","journal-title":"Science"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/01.HYP.35.1.150","article-title":"Implications of species difference for clinical investigation: studies on the renin-angiotensin system","volume":"35","author":"Hollenberg","year":"1999","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1152\/physrev.1974.54.4.1007","article-title":"Pharmacokinetic function of the pulmonary circulation","volume":"54","author":"Bakhle","year":"1974","journal-title":"Physiol Rev"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","article-title":"Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans","volume":"95","author":"Hornig","year":"1997","journal-title":"Circulation"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.RES.9.5.1044","article-title":"Renin and angiotensin tachyphylaxis","volume":"9","author":"Bock","year":"1961","journal-title":"Circ Res"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0014-5793(87)80914-6","article-title":"Angiotensin I-converting enzyme in isolated human glomeruli","volume":"220","author":"Chansel","year":"1987","journal-title":"FEBS Lett"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/01.CIR.53.3.400","article-title":"The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects","volume":"53","author":"Sancho","year":"1976","journal-title":"Circulation"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1440-1681.1986.tb00311.x","article-title":"Time course of changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double-blind randomized study vs hydrochlorothiazide plus propranolol in essential hypertension","volume":"13","author":"Semplicini","year":"1986","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1152\/ajplegacy.1970.219.6.1751","article-title":"Central inhibition of reflex vasodilatation by angiotensin and reduced renal pressure","volume":"219","author":"Sweet","year":"1970","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB10|cit10","first-page":"R358","article-title":"Central site for pressor action of blood-borne angiotensin in rat","volume":"239","author":"Fink","year":"1980","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s001090100210","article-title":"Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research","volume":"79","author":"Bader","year":"2001","journal-title":"J Mol Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00001573-200111000-00002","article-title":"The clinical implication of tissue renin angiotensin systems","volume":"16","author":"Re","year":"2001","journal-title":"Curr Opin Cardiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/j.1523-1755.2005.00675.x","article-title":"Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors","volume":"68","author":"Ferrario","year":"2005","journal-title":"Kidney Int"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1113\/expphysiol.2007.041855","article-title":"Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats","volume":"93","author":"Hamming","year":"2008","journal-title":"Exp Physiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI116325","article-title":"Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart","volume":"91","author":"Urata","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/00005344-199811000-00020","article-title":"Functional role of chymase in angiotensin II formation in human vascular tissue","volume":"32","author":"Takai","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0895-7061(95)96211-2","article-title":"Progressive improvement in the structure of resistance arteries of hypertensive patients after 2\u2003years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker","volume":"8","author":"Schiffrin","year":"1995","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.HYP.31.1.181","article-title":"Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis","volume":"31","author":"Border","year":"1998","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJM197702242960801","article-title":"Mild high-renin essential hypertension: neurogenic human hypertension?","volume":"296","author":"Esler","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00004872-199101000-00012","article-title":"Hyperkinetic borderline hypertension in Tecumseh, Michigan","volume":"9","author":"Julius","year":"1991","journal-title":"J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/0002-9149(82)90243-0","article-title":"Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure","volume":"49","author":"Levine","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.31.5.1088","article-title":"Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives","volume":"31","author":"Weir","year":"1998","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0895-7061(95)00300-2","article-title":"Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril","volume":"9","author":"Moore","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/01.HYP.13.4.371","article-title":"Prolonged converting enzyme inhibition in non-modulating hypertension","volume":"13","author":"Dluhy","year":"1989","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ki.1978.171","article-title":"Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension","volume":"14","author":"Weidmann","year":"1978","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1111\/j.1751-7176.2011.00508.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000212919","article-title":"Influence of age on blood pressure response to enalapril","volume":"33","author":"Cooper","year":"1987","journal-title":"Gerontology"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/01.HYP.1.2.136","article-title":"Racial differences in pressure, volume and renin interrelationships in essential hypertension","volume":"1","author":"Chrysant","year":"1979","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/dtb.2008.09.0020","article-title":"Blood pressure guidelines - where are we now?","volume":"46","year":"2008","journal-title":"Drug Ther Bull"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB122|cit30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/ajkd.2002.34489","article-title":"ACE genotype and ACE inhibitor response in kidney disease: a perspective","volume":"40","author":"Mayer","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1681\/ASN.V11188","article-title":"Chronic proteinuric nephropathies II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (GISEN)","volume":"11","author":"Ruggenenti","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0002-9149(96)00198-1","article-title":"Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension","volume":"77","author":"Gharavi","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2215\/CJN.04140907","article-title":"Angiotensin converting enzyme insertion\/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies","volume":"3","author":"Ruggenenti","year":"2008","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1161\/hy1101.099502","article-title":"Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy","volume":"38","author":"Svensson","year":"2001","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB40|cit40","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","article-title":"The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction","volume":"332","author":"Ambrosioni","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB44|cit44","first-page":"1115","article-title":"Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction","volume":"343","author":"Gruppo GISSI 3","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Fourth International Study of Infarct Survival (ISIS-4)","volume":"345","author":"Fourth International Study of Infarct Survival (ISIS-4)","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0140-6736(95)90866-8","article-title":"Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CC-1)","volume":"345","author":"Chinese Collaborative Study Coordinating Group","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1161\/01.CIR.0000134791.68010.FA","article-title":"ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Group","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(03)13501-5","article-title":"Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study","volume":"361","author":"Jong","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Int Medicine"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Eng J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. [see comment]","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archinte.168.8.832","article-title":"Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans","volume":"168","author":"Appel","year":"2008","journal-title":"Arch Int Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"Progress Collaborative Group","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.hjh.0000226212.34055.86","article-title":"Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial","volume":"24","author":"Arima","year":"2006","journal-title":"J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archinte.163.9.1069","article-title":"Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease","volume":"163","author":"Tzourio","year":"2003","journal-title":"Arch Int Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","article-title":"Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR\/Trandolapril STudy","volume":"55","author":"Bavry","year":"2010","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0140-6736(77)92958-0","article-title":"A specific orally active inhibitor of angiotensin-converting enzyme in man","volume":"1","author":"Ferguson","year":"1977","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1254\/jjp.54.143","article-title":"A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans","volume":"54","author":"Kawamura","year":"1990","journal-title":"Jpn J Pharmacol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1592\/phco.19.8.655.31524","article-title":"Physician prescribing patterns of ACE inhibitors in secondary prevention post myocardial infarction","volume":"19","author":"Luzier","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0002-9149(98)00361-0","article-title":"Impact of angiotensin-converting enzyme inhibitors underdosing on rehospitalization rates in congestive heart failure","volume":"82","author":"Luzier","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0002-9149(00)01005-5","article-title":"Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization","volume":"86","author":"Luzier","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00005344-198211000-00014","article-title":"Antihypertensive therapy with MK 421: angiotensin II - renin relationships to evaluate efficacy of converting enzyme blockade","volume":"4","author":"Biollaz","year":"1982","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1524-6175.2004.03511.x","article-title":"Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials","volume":"6","author":"Izzo","year":"2004","journal-title":"J Clin Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"10.1111\/j.1751-7176.2011.00508.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"135s","DOI":"10.1042\/cs057135s","article-title":"Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension","volume":"57","author":"Matthews","year":"1979","journal-title":"Clin Sci"},{"issue":"suppl 2","key":"10.1111\/j.1751-7176.2011.00508.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000174555","article-title":"Clinical pharmacology of ACE inhibition","volume":"76","author":"Nussberger","year":"1989","journal-title":"Cardiol"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1161\/01.CIR.96.4.1173","article-title":"Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure","volume":"96","author":"Grassi","year":"1997","journal-title":"Circulation"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1046\/j.1532-5415.2002.50321.x","article-title":"Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?","volume":"50","author":"Ahmed","year":"2002","journal-title":"J Am Geriatrics Soc"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Int Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00004872-200204000-00037","article-title":"Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs","volume":"20","author":"Deary","year":"2002","journal-title":"J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","article-title":"2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 Express","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"151","author":"Mann","year":"2009","journal-title":"Ann Internal Med"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ahj.2006.02.028","article-title":"Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM)-added trial","volume":"151","author":"McMurray","year":"2006","journal-title":"Am Heart J"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.ajkd.2008.03.008","article-title":"Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression","volume":"52","author":"Catapano","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1751-7176.2011.00508.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jash.2010.02.005","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"J Am Soc Hyperten"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1751-7176.2011.00508.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T04:26:52Z","timestamp":1638073612000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1751-7176.2011.00508.x"}},"subtitle":["Angiotensin-Converting Enzyme Inhibitors"],"short-title":[],"issued":{"date-parts":[[2011,7,18]]},"references-count":92,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00508.x","relation":{},"ISSN":["1524-6175"],"issn-type":[{"value":"1524-6175","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,18]]}}}